Compare Amylx Pharmaceuticals Inc (AMLX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs 22nd Century Group Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 1736.8× 22nd Century Group Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | XXII | |
|---|---|---|
Market Cap | $2.64B | $1.52M |
Sector | Health | Technology |
52-Week High | $24.19 | $801.00 |
52-Week Low | $7.82 | $3.72 |
Enterprise Value | $2.39B | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
22nd Century Group (XXII) trades at $4.31, down 0.92% on the day, with a neutral technical signal and bearish moving averages. The company shows deep unprofitability with a gross margin of -52.19% and net margin of -65.76%, though revenue was $7.05M in 2025. Recent corporate actions include a 20:1 reverse stock split in June 2026, and news highlights retail expansion for VLN reduced-nicotine cigarettes in California and New York.
The outlook remains speculative with high execution risk amid persistent losses, but analyst sentiment is bullish with 75% buy ratings. Key risks include negative cash flow from operations, regulatory hurdles for tobacco products, and the need for successful commercialization of VLN to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
